Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
about
HIV infection and cardiovascular diseaseSoluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Cardiovascular Complications of HIV Infection.High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.Low HDL-cholesterol among HIV-1 infected and HIV-1 uninfected individuals in Nairobi, Kenya.Residual immune dysregulation syndrome in treated HIV infection.Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Biomarkers and HIV-associated cardiovascular disease.HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.Biomarkers of immune dysfunction in HIV.HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infectionPlasma levels of soluble CD14 independently predict mortality in HIV infection.Cardiovascular implications from untreated human immunodeficiency virus infection.Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothersThe CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals.Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens.Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAARTReduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection.Dyslipidemia and lipid management in HIV-infected patientsLipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort.HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque.Correlation between HIV disease and lipid metabolism in antiretroviral-naïve HIV-infected patients in Japan.Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.Incident hypertension in older women and men with or at risk for HIV infection.Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).High-Density Lipoprotein Subclasses and Noncardiovascular, Noncancer Chronic Inflammatory-Related Events Versus Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis.Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral TherapyCardiometabolic risk factors among HIV patients on antiretroviral therapy.Current understanding of HIV-associated neurocognitive disorders pathogenesis.Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy.Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study.Microbial translocation and metabolic and body composition measures in treated and untreated HIV infection
P2860
Q27008915-5116A3E7-B965-4407-891C-AAA81A794340Q27690715-A3528809-F7F9-496F-917A-EABC557C964BQ28086787-EE2A84FD-25B5-4EEB-83B9-2035570E96E0Q30235920-399A2220-3FE8-414B-83F9-6558BBB1A607Q33556997-441B757E-7422-45B7-B1E8-70BBA0BA7BFAQ33785181-0C6593D4-0BCA-4DC7-863D-F4695CB79EBAQ34020121-E5ECFBF1-90B3-48AF-97A8-18A90BDB8823Q34079197-5BB7382C-2DE1-4E63-8605-767022D25C2DQ34146122-4F7BEF9B-BEF2-4773-B92A-0E1BA4F70904Q34315572-881D8EAD-C8A6-4358-8E89-23E5E67E4C1CQ34335486-803C1814-B2F4-4CF6-A343-A1DDD7F924D7Q34355660-3C14C352-28EE-40AD-941F-9E62A4878DEFQ34546742-71C2BD80-2578-4CEC-8E36-D3E6C98B32B0Q34712485-43AE9CEF-662E-43C3-AE97-4E1B9C33C683Q34764002-5E766523-6CF6-44F1-A056-227CC0514071Q34793193-5027C9BE-09B0-4BB8-8352-CCBE098684EBQ34881120-8F9F0EC1-8B03-4D4E-BB19-F20F49F01EEEQ35030351-4F1D6FAD-2955-4FA0-B50E-2F3511B3F9A5Q35036648-6489DF35-0400-45DD-8A4B-34C10FF42C52Q35051199-671390C2-20F5-4B1C-8379-BC4247845161Q35120957-EFDF1CE8-D3F4-4D7F-93BA-B4E44508787DQ35122438-A02DBA59-C754-4B6A-B4BE-3ACAE1A66922Q35160574-82BA72F6-9495-4B0D-90EA-79B7137107AEQ35209036-CCC10F52-64A4-44B2-A330-CD899E60FA1CQ35579905-E906B757-55D4-42FE-9BE0-A80CD4A1E7BFQ35754336-A2F29C41-48C7-4659-B0C0-E988FFF9364BQ35847854-04C5126C-FD10-42D3-B25C-9C7A291DA300Q35873877-B4148301-511A-4ADC-899D-2A1D4EEF162CQ36067337-5D05ABF1-FA27-48E5-8B08-A07F490641BCQ36087108-17FF2A11-7120-4562-8413-F98913F05C50Q36132003-FC3953D1-4925-4756-8465-34D6D842F319Q36139932-44976C82-A56C-47EA-AA64-09B1D4199886Q36141889-70293216-EE3E-44BF-A6B5-3B6C697AF5E2Q36656763-9976E2C8-A846-4C51-9431-1A156A070C6FQ36808820-59392216-34B1-4B4C-90AE-9298B54F7A0DQ36932005-BEA4BC09-ADD1-4AEA-9A8D-42FC4573CF71Q37165196-F7916870-1134-484B-96ED-FE1C2C877D31Q37319195-3A095D6F-B433-44AD-AE7F-3AA554504A0BQ37355492-F174D298-BCBD-4257-9049-5E3F972DE105Q37610700-A4CBE05E-9B8F-4443-B6B8-D2C02CFE9606
P2860
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
@ast
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
@en
type
label
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
@ast
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
@en
prefLabel
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
@ast
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
@en
P2093
P2860
P1433
P1476
Lipoprotein particle subclasses, cardiovascular disease and HIV infection
@en
P2093
Angelike P Liappis
Daniel A Duprez
David A Cooper
Fiona Lampe
INSIGHT SMART Study Group
Jacqueline Neuhaus
James D Neaton
James Otvos
Lewis H Kuller
Nicholas I Paton
P2860
P304
P356
10.1016/J.ATHEROSCLEROSIS.2009.05.001
P577
2009-05-13T00:00:00Z